newsfilter
← Latest News
Business Wire·

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to